Over the last 30 years, the five-year survival rate of patients with brain cancer in Australia hasn’t changed, remaining at about 22%. Now, researchers are planning to launch a clinical trial platform that will revolutionize studies on new treatments for brain cancer and help deliver more personalized and targeted therapies for patients not just in Australia but around the world.
The platform, titled the Brain-POP (brain perioperative), will allow physicians to observe the effect of a new drug treatment on a brain-cancer patient by comparing samples of tumors obtained prior to and following therapy administration.
The platform will be the first of its kind globally. It has been awarded millions in funding from the Victorian government and is led by the Brain Cancer Center and research partners including the Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, the Royal Children’s Hospital, Peter MacCallum Cancer Center and the University of Melbourne.
The Brain Cancer Center’s laboratory head, Dr. Jim Whittle, stated that this platform would help address the lack of trial options available to patients with brain cancer while also allowing findings from studies to be translated to clinic works. Whittle also stated that the lack of progress over the last three decades highlighted the need to completely change the process of drug development and how brain cancer clinical trials were ran.
In addition, Whittle noted that the platform provided a new approach to help clinicians test whether a drug penetrated the brain and if it could produce the desired effect.
The Royal Melbourne Hospital’s director of neurosurgery, Professor Kate Drummond, stated that the integrated and collaborative program would make use of researcher and clinician expertise, adding that the platform’s new approach would also put the country at the forefront of research on brain cancer.
This clinical trial program will deliver innovative clinical trials with adult, adolescent and pediatric patients that will enable scientists to generate a holistic picture on the treatment of brain cancer that has, thus far, been absent from research.
Jaala Pulford, the country’s minister for innovation, Medical Research and the Digital Economy, stated that this unique program would help save the lives of many adults, adolescents and children with primary brain cancer and brain metastases. Pulford added that there was an urgent need to discover more curative and effective brain-cancer treatments, noting that as a leader in medical research and cancer care, Victoria was well positioned to be at the forefront of this groundbreaking work.
As the research efforts of various parties such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) push the envelope of what is possible in brain-cancer treatment, patients will be the net beneficiaries as better alternatives are brought to market.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.